In summary, our study highlights the potential of the STING agonist c‐di‐AMP, in synergy with ginsenoside Rg3, to impede the progression of SGC‐7901/DDP cells, providing a promising avenue for future cancer therapeutics. The gene discussed is STING1; the disease is cancer.